A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

PURPOSE: This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in patients with advanced malignancies. METHODS: We conducted a fixed-sequence, single-blind, placebo-controlled study. Patients (n = 23) received...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2012
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3456920/
https://ncbi.nlm.nih.gov/pubmed/22878520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1942-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky